US · CDXS · BIOTECHNOLOGY
Codexis, Inc. (CDXS) intrinsic value and stock valuation
$1.01as of 2026-11-21 · Mkt cap 131.76M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Codexis, Inc. DCF and intrinsic value
InvestorsCraft values CDXS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CDXS’s statements →
Codexis, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $70.4M | $59.3M | $70.1M | $138.6M | $104.8M |
| Operating income | -$-38.33M | -$-58.52M | -$-68.07M | -$-34.88M | -$-22.7M |
| Net income | -$-43.97M | -$-65.28M | -$-76.24M | -$-33.59M | -$-21.28M |
| EPSd | -$-504.59K | -$-889.25K | -$-1.12M | -$-514.08K | -$-329.56K |
| Operating cash flow | -$-19.38M | -$-49.41M | -$-52.64M | $11.3M | -$-14.27M |
| Capital expenditure | -$-4.47M | -$-4.3M | -$-4.42M | -$-8.31M | -$-13.83M |
| Free cash flow | -$-23.85M | -$-53.72M | -$-57.06M | $2.98M | -$-28.09M |
| Total assets | $147.8M | $149M | $136.6M | $250.4M | $246.4M |
| Total debt | $73.2M | $59.9M | $16M | $43.6M | $47.7M |
| Net debt | $22.4M | $40.6M | -$-49.09M | -$-70.35M | -$-69.14M |
| Total equity | $50.5M | $66.9M | $86.6M | $144.8M | $164.4M |
| Cash and short-term investments | $78.2M | $73.5M | $65.1M | $114M | $116.8M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $70.4M | $59.3M | $70.1M | $138.6M | $104.8M |
| Cost of revenue | $9.34M | $16.3M | $12.8M | $38M | $22.2M |
| Gross profit | $61.1M | $43.1M | $57.3M | $100.6M | $82.6M |
| Research and development expenses | $52.3M | $46.3M | $58.9M | $80.1M | $55.9M |
| Selling, general and administrative expenses | $47.1M | $55.2M | $53.3M | $52.2M | $49.3M |
| Other expenses | $0.00 | $170K | $13.3M | $3.17M | $0.00 |
| Operating expenses | $99.4M | $101.6M | $125.4M | $135.4M | $105.2M |
| Cost and expenses | $108.7M | $117.9M | $138.2M | $173.5M | $127.5M |
| Interest income | $2.62M | $3.67M | $4.17M | $1.44M | $460K |
| Interest expense | $4.81M | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $5.25M | $4.95M | $5.52M | $5.4M | $5.95M |
| Ebitda | -$-33.87M | -$-53.41M | -$-49.28M | -$-26.31M | -$-15.14M |
| Operating income | -$-38.33M | -$-58.52M | -$-68.07M | -$-34.88M | -$-22.7M |
| Total other income/expenses, net | -$-5.59M | -$-6.72M | -$-8.1M | $1.56M | $1.61M |
| Income before tax | -$-43.93M | -$-65.24M | -$-76.17M | -$-33.32M | -$-21.09M |
| Income tax expense | $50K | $30K | $70K | $280K | $190K |
| Net income | -$-43.97M | -$-65.28M | -$-76.24M | -$-33.59M | -$-21.28M |
| Weighted average shares outstanding | $87.1M | $73.4M | $68.1M | $65.3M | $64.6M |
| Weighted average diluted shares outstanding | $87.1M | $73.4M | $68.1M | $65.3M | $64.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $78.2M | $73.5M | $65.1M | $114M | $116.8M |
| Net receivables | $10.7M | $18.9M | $19.9M | $40.9M | $37.7M |
| Inventory | $1.82M | $1.8M | $2.69M | $2.03M | $1.16M |
| Total current assets | $96.8M | $98.8M | $93.5M | $162.9M | $161.9M |
| Property, plant and equipment, net | $43.5M | $42.9M | $28.6M | $61.9M | $65.5M |
| Goodwill and intangible assets | $2.46M | $2.46M | $2.46M | $3.24M | $3.24M |
| Long-term investments | $2.5M | $2.8M | $9.7M | $20.5M | $14M |
| Total non-current assets | $51M | $50.2M | $43.1M | $87.5M | $84.5M |
| Total assets | $147.8M | $149M | $136.6M | $250.4M | $246.4M |
| Accounts payable | $1.55M | $2.84M | $5.95M | $3.25M | $3M |
| Short-term debt | $2.94M | $2.83M | $3.78M | $5.36M | $4.09M |
| Deferred revenue | $7.01M | $350K | $10.1M | $13.7M | $2.59M |
| Total current liabilities | $25.3M | $23.7M | $35.8M | $49.1M | $33.4M |
| Long-term debt | $70.3M | $57.1M | $12.2M | $38.3M | $43.6M |
| Deferred revenue, non-current | $360K | $100K | $640K | $16.9M | $3.75M |
| Total non-current liabilities | $72M | $58.4M | $14.1M | $56.5M | $48.6M |
| Capital lease obligations | $33.1M | $31M | $16M | $43.6M | $47.7M |
| Total liabilities | $97.3M | $82.1M | $50M | $105.6M | $82M |
| Common stock | $10K | $10K | $10K | $10K | $10K |
| Retained earnings | -$-606.78M | -$-562.81M | -$-497.53M | -$-421.29M | -$-387.7M |
| Accumulated other comprehensive income (loss) | $10K | $50K | $0.00 | $0.00 | $0.00 |
| Total equity | $50.5M | $66.9M | $86.6M | $144.8M | $164.4M |
| Total investments | $29.9M | $57M | $9.7M | $20.5M | $14M |
| Total debt | $73.2M | $59.9M | $16M | $43.6M | $47.7M |
| Net debt | $22.4M | $40.6M | -$-49.09M | -$-70.35M | -$-69.14M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-43.97M | -$-65.28M | -$-76.24M | -$-33.59M | -$-21.28M |
| Depreciation and amortization | $5.25M | $4.95M | $9.92M | $10.3M | $5.95M |
| Stock-based compensation | $9.62M | $13.1M | $9.97M | $14.5M | $11.6M |
| Change in working capital | $6.42M | -$-12.02M | -$-18.22M | $21.6M | -$-7.62M |
| Accounts receivable | $8.51M | $1.25M | $20.3M | -$-3.23M | -$-15.57M |
| Inventory | -$-20K | $890K | -$-660K | -$-870K | -$-200K |
| Accounts payable | -$-1.29M | -$-2.57M | $2.29M | $210K | $270K |
| Net cash provided by operating activities | -$-19.38M | -$-49.41M | -$-52.64M | $11.3M | -$-14.27M |
| Investments in property, plant and equipment | -$-4.47M | -$-4.3M | -$-4.42M | -$-8.31M | -$-13.83M |
| Acquisitions, net | $10K | $90K | $750K | $30K | $40K |
| Net cash used for investing activities | $23.5M | -$-56.98M | -$-4.86M | -$-13.58M | -$-21.42M |
| Common stock issued | $18M | $31.3M | $8.65M | $910K | $4.97M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $27.9M | $60.5M | $8.17M | -$-570K | $3.77M |
| Net change in cash | $32.1M | -$-45.87M | -$-49.33M | -$-2.87M | -$-31.92M |
| Cash at end of period | $52.9M | $20.8M | $66.7M | $116M | $118.9M |
| Operating cash flow | -$-19.38M | -$-49.41M | -$-52.64M | $11.3M | -$-14.27M |
| Capital expenditure | -$-4.47M | -$-4.3M | -$-4.42M | -$-8.31M | -$-13.83M |
| Free cash flow | -$-23.85M | -$-53.72M | -$-57.06M | $2.98M | -$-28.09M |
Line items
Line items
Line items
About Codexis, Inc.
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
- CEO
- Alison Moore
- Employees
- 146
- Beta
- 2.50
Explore
Frequently asked questions
What is the intrinsic value of Codexis, Inc. (CDXS)?
InvestorsCraft does not currently publish an intrinsic value for CDXS. How the IC value is calculated.
Is CDXS undervalued?
InvestorsCraft does not publish an undervaluation signal for CDXS at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.